Innovative Vaccine Portfolio Merck Animal Health USA has recently launched advanced vaccines such as NOBIVAC NXT Rabies and Canine-3 leveraging RNA-particle technology, highlighting opportunities to promote cutting-edge biopharma solutions for companion animal health.

Expanding Manufacturing Capacity The company's significant investments of $895 million in expanding manufacturing and R&D facilities in Kansas and Missouri present opportunities to provide specialized equipment, raw materials, and process innovations to support large molecule vaccine production.

Focus on Disease Prevention With new tools designed to prevent and treat diseases like New World screwworm and Porcine Circovirus, there is potential to offer diagnostics, therapeutics, or complementary health solutions that enhance disease management in livestock.

Sustainability and Welfare Built on a foundation of fish health and welfare, Merck's strong focus on animal well-being creates avenues to introduce environmentally sustainable products or technologies that reduce impact and improve health outcomes.

Growth and Innovation Recent technological partnerships such as virtual fencing for Felton Angus Ranch indicate openness to innovative livestock management solutions, opening doors to integrated tech-based services, IoT devices, and data analytics for modern animal agriculture.